Venn Life Sciences Share Discussion Threads

[mr hangman] 07/4/2017 12:35

Wish i could hang around a thread, where i don't even own any shares

[cocker] 07/4/2017 12:29

Wow, what a toss pot of an answer

[mr hangman] 07/4/2017 11:49

Unlike you, they are professional investors who know the risks

[cocker] 07/4/2017 11:34

Right. What buy a share & over months watch it's value dissappear. Anyone who took up in the skin ipo are down over 20%, shall we tell them don't worry, it's a long term game.

[cocker] 07/4/2017 11:06

Mr Hangman . Can you please advise on Skin share price today. Mid price now less then 20% ipo. Shocking

[mulligut] 06/4/2017 11:46

Earlier I setup a new thread for SKIN - Integumen. But as Rivaldo rightly pointed out, I never put the name of the company into the header. So much for search capacilities. So I have set up another thread of a similar header, but included the name.

Just goes to show how many threads I have set up. The new thread is at

[mulligut] 06/4/2017 09:43

I have started a thread on Integumen (SKIN)

I would welcome all on here to contribute, positive or otherwise. LBO if you do decide please, at least, try to be constructive. I will go along with the concept that just because you are paranoid does not mean they are out to get you, but surely after 3 years you might be fed up with singing the same old song and provide substance to current issues here and if you join the new thread.

Good luck to all.

[mulligut] 06/4/2017 09:26

VENN have completed a number of acquisitions, employed over 200 people, have doubled their turnover, have multi-national pharma clients and spun out a subsidiary that has also listed on AIM.

These guys are building a business and thus far have made a reasonably decent go at it. Of the 200 or so members of staff it looks like he may have some negative hostility towards management that was in Alltracel, so the only one I can see is their CEO. In which case I am still trying to see what it has to do with VENN. It has a Board of Directors who have appointed the CEO, a CFO who is likely to be a qualified accountant who would not wish to be associated with any underhanded issues and a robust FCA, Nomad and institutional investors who have backed management.

Having bought shares in this company month after month for the last 2 years at least I prefer to invest in a minuscule way like Buffett. If the company is good, the business model is good, management has shown progress, it is easy to understand how the revenues are earned and there is long term growth opportunity then I think it is a safe bet for my pension.

I have tried to see what LBO has to say that makes a case that contradicts the above. At some point if he continues to repeat the same old tripe then it can be as simple as blocking him from my feed on this thread.

[aishah] 05/4/2017 15:44

Design a Smart Clinical Trial with an Adaptive Study Design

venn-adaptive-study-design

By using smart designs, sponsors can save time and money while optimizing the knowledge accrued during the development of their products.

“Traditional” study designs and statistical methodology do not allow changing the main features of a study protocol once the study has been initiated. The use of interim analyses, and in particularly the development of group sequential analysis methods introduces some flexibility in the study designs by allowing interruption of treatment arms (or the whole study) after early demonstration of efficacy (or evidence of futility) at a planned interim analysis.

Advances in the methodology of clinical studies provide even more flexibility by allowing the modification of some features of the design based on information collected during interim analyses. Such a setup is known as an adaptive study design, or among other designations a flexible, smart or multistage design.

In its 2004 Innovation/Stagnation: Challenge and Opportunity on the Critical Path to New Medical Product report, the US Food and Drug Administration (FDA) identified an urgent need to improve the efficiency and effectiveness of the clinical trial process, including trial design, endpoints, and analyses, and stated that in many cases, developers have no choice but to use the tools and concepts of the last century to assess this century’s candidates[1]. In the following Critical Path Initiative Opportunities List (March 2006), adaptive designs are identified as one way to streamline Clinical Trials[2]. The Regulatory bodies have issued guidance documents on the topic of adaptive designs. The EMA document was adopted in 2007[3] while the FDA draft guidance was issued in 2010[4].

The methodology experts at Venn Life Sciences have risen to the challenge by providing expertise and experience in helping clients to design such adaptive clinical studies.



Labiotech.eu is the leading digital media covering the European Biotech industry. Over 70,000 monthly visitors use it to keep an eye on the business and innovations in biotechnology. Hope you'll enjoy reading our stories!

[rivaldo] 05/4/2017 15:43

In summary, VENN now have against a £10m m/cap:

- £3m of cash
- £1.9m of Integumen shares at the current 4.5p bid price
- a business turning over 18m euros and rising
- forecast earnings per Hybridan at 31st March of:

this year - 1,58p EPS (£1.1m PBT)
next year - 1.79p EPS (£1.36m PBT)

The current m/cap is crazy on those figures. Even if you discount the Integumen shares, and halve the analyst forecasts, the valuation remains extremely low. IMHO anyway.

[lbo] 05/4/2017 15:07

Only last May forecasts were 2.5c for this year which they did not achieve.

[rivaldo] 05/4/2017 15:04

Agreed - the forecast for this year of 1.58p EPS can't be relied upon until we get confirmation of bottom line profitability, whether at the AGM in 3 weeks or with the H1 trading update. VENN did make €0.39m positive EBITDA last year.

One would hope that Hybridan - having been so badly wrong with last year's figures - would have consulted much more closely with VENN this time before putting out their forecasts.

We may also get an acquisition using the cash pile, hopefully sooner rather than later.

In summary, this company, with £5m/50% of its m/cap in liquid assets as I've already laid out, seems to me to be good value anyway given in addition the high and growing turnover and the positive start to this year. There are plenty of companies out there with tiny cash balances and miniscule turnover valued at multiples of VENN's £10m m/cap.

[cocker] 05/4/2017 15:03

Fair comment Yump

[yump] 05/4/2017 14:45

I'm taking next year's eps as a finger in the air job, because there is no reliable record of cost reduction to extrapolate against revenue and this year's doesn't count, because of the one-off.

Hanging on because the positive is that they effectively had the same loss as last year, but on 50% higher revenue, rather than increasing losses. There's been loads of companies who just keep increasing losses as revenue goes up.

Willing to give it 6 months and see what the interims show. Whether they will break down costs or not... no idea, but they should at some point.

[lbo] 05/4/2017 11:17

Heard it all before. Yet they still sold the company for a fraction of what they IPO athttps://www.irishtimes.com/business/profitability-in-sight-as-alltracel-cuts-2005-losses-1.1037276

[cocker] 05/4/2017 11:12

Looks great Rivaldo & one could easily invest on those figure's. However, that picture does not tell the true story & the market has reacted accordingly. Who is right & who is wrong will always lead to a good debate, but how often does the market get it so wrong, not that often is my guess.

[aishah] 05/4/2017 10:52

And that's why I have kept on adding rivaldo.

[rivaldo] 05/4/2017 10:41

In summary then, VENN now have against a £10m m/cap:

- £3m of cash
- £1.9m of Integumen shares at the current 4.5p bid price
- a business turning over 18m euros and rising
- forecast earnings per Hybridan at 31st March of:

this year - 1,58p EPS (£1.1m PBT)
next year - 1.79p EPS (£1.36m PBT)

The current m/cap is crazy on those figures. Even if you discount the Integumen shares, and halve the analyst forecasts, the valuation remains extremely low. IMHO anyway.

[timbo003] 05/4/2017 09:39

The SKIN IPO was at 5p, current price 5p (offer)

That doesn't look like down 20% to me

[lbo] 05/4/2017 09:27

History repeats itself with this crowdhttps://www.irishtimes.com/business/alltracel-slumps-on-london-launch-1.318735?mode=amp